Skip to Main Content

An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors

Principal Investigator

Chukwuemeka Ikpeazu

Clinical Trial ID

Institutional Protocol # 20160142
National Clinical Trials Identifier NCT02303444

Clinical Trial Summary

The purpose of the study is to assess the use of Multikinase Inhibitors (MKIs) in the
treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory to
radioactive iodine (RAI) who do not have any symptoms.



Funding Agency/Sponsor



Thyroid and Other Endocrine Cancers

Enrollment Eligibility

Inclusion Criteria:
- Histologically/cytologically documented DTC (papillary, follicular, Hurthle cell, and
poorly differentiated carcinoma)
- DTC refractory to RAI
- Radiological progression and preferably according to RECIST 1.1
- No symptoms due to DTC
- >/=1cm diameter of lesion confirmed by radiological exam
- Life expectancy of at least 6 months
Exclusion Criteria:
- Plan to be treated according to a clinical trial protocol for intervention including a
locoregional therapy or systemic therapy
- Previous treatment with MKIs for advanced disease
- Hospice patients

Contact Information

Study Contact Cancer Center Studies
Phone Number 1-866-574-5124
Get detailed information on ClinicalTrials.Gov